Clinical Data Revolution rockets on strong pancreatic cancer data PharmaphorumRevolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.Clinical DataOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story Post navigation Previous: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priorityNext: Novo Nordisk and OpenAI forge alliance to drive speedy drug development Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
